BioMarin Pharmaceutical Inc.
General ticker "BMRN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $10.8B (TTM average)
BioMarin Pharmaceutical Inc. follows the US Stock Market performance with the rate: 7.6%.
Estimated limits based on current volatility of 1.8%: low 59.60$, high 61.79$
Factors to consider:
- Earnings expected soon, date: 2026-08-03 amc
- Total employees count: 3221 (+6.0%) as of 2025
- Top business risk factors: Regulatory and compliance, Economic downturns and volatility, Supply chain disruptions, Manufacturing process failures, Intellectual property risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [43.90$, 70.10$]
- 2026-12-31 to 2027-12-31 estimated range: [48.17$, 75.31$]
Financial Metrics affecting the BMRN estimates:
- Negative: with PPE of 24.4 at the end of fiscal year the price was very high
- Positive: 7.78 < Operating profit margin, % of 12.71
- Positive: Inventory ratio change, % of -1.33 <= -0.76
- Positive: 6.73 < Operating cash flow per share per price, % of 7.21
- Negative: Shareholder equity ratio, % of 80.16 > 63.79
- Positive: Interest expense per share per price, % of 0.09 <= 0.75
- Positive: 1.89 < Return on assets ratio (scaled to [-100,100]) of 4.39
Short-term BMRN quotes
Long-term BMRN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,419.23MM | $2,863.91MM | $3,221.25MM |
| Operating Expenses | $2,233.45MM | $2,379.70MM | $2,811.78MM |
| Operating Income | $185.77MM | $484.21MM | $409.48MM |
| Non-Operating Income | $2.79MM | $57.55MM | $73.00MM |
| Interest Expense | $17.34MM | $12.67MM | $10.90MM |
| R&D Expense | $746.77MM | $747.18MM | $921.93MM |
| Income(Loss) | $188.56MM | $541.76MM | $482.48MM |
| Taxes | $20.92MM | $114.90MM | $133.58MM |
| Net Income(Loss)* | $167.65MM | $426.86MM | $348.90MM |
| Stockholders Equity | $4,951.55MM | $5,657.99MM | $6,087.00MM |
| Inventory | $1,107.18MM | $1,232.65MM | $1,298.88MM |
| Assets | $6,841.60MM | $6,988.94MM | $7,594.02MM |
| Operating Cash Flow | $159.26MM | $572.84MM | $827.99MM |
| Capital expenditure | $107.61MM | $97.42MM | $103.04MM |
| Investing Cash Flow | $-111.24MM | $136.49MM | $-414.24MM |
| Financing Cash Flow | $-18.73MM | $-526.45MM | $-42.39MM |
| Earnings Per Share** | $0.89 | $2.25 | $1.82 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.